Bruker (BRKR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$58.50-1.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · BRKR
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(6.4) + peer(0.2*4.8) + term(0.0) → 3.21% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 4, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 6, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…
Results of Operations and Financial Condition. On February 12, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated…
Results of Operations and Financial Condition. On January 12, 2026, during its scheduled presentation at the 44th Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter ended December 31, 2025 is between $965 million and $970 million and that fourth quarter 2025 Bruker Scientific Instruments segments book-to-bill ratio was above 1.0. The Company also provided a preliminary outlook for the…
Results of Operations and Financial Condition. On November 3, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by re…
Results of Operations and Financial Condition. On August 4, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference…
Results of Operations and Financial Condition. On July 21, 2025, Bruker Corporation (the “Company”) issued a press release announcing unaudited preliminary results for the second quarter of 2025. A copy of the press release is attached hereto as Exhibit 99.1. The financial results referred to in the press release are unaudited and preliminary estimates that (i) represent the most current information available to management as of the date of this Current Report on Form 8-K, (ii) are subject to…
Results of Operations and Financial Condition. On May 7, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…
Results of Operations and Financial Condition. On April 11, 2025, Bruker Corporation (the “Company”) issued a press release announcing unaudited preliminary revenue for the three months ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The financial results referred to in the press release are unaudited and preliminary estimates that (i) represent the most current information available to management as of the date of this Current Report on Form 8-K, (ii) ar…
Results of Operations and Financial Condition. On February 13, 2025, Bruker Corporation issued a press release announcing financial results as of and for the three months and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by re…
Results of Operations and Financial Condition. On January 13, 2025, during its scheduled presentation at the 43rd Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter of 2024 is between $970 million and $980 million and that fourth quarter 2024 BSI bookings were solid. The Company also provided preliminary outlook for 2025 for constant exchange rate revenue growth of upper mid-single dig…
Results of Operations and Financial Condition. On November 5, 2024, Bruker Corporation issued a press release announcing financial results as of and for the three and nine months ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by re…
Results of Operations and Financial Condition. On August 6, 2024, Bruker Corporation issued a press release announcing financial results as of and for the three and six months ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference…
Results of Operations and Financial Condition. On May 2, 2024, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…